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Abstract
Choriocarcinoma is a highly malignant and rare tumor characterized by secretion of the beta-subunit-of-human-choriogonad-
otropin (β-HCG).
We report a case of primary nasal choriocarcinoma with good response to chemotherapy.
A 36-years-old woman gravida 0 and with history of 4 spontaneous abortion, in December 2018 referred to Otorhinolaryngology 
Department for repeated episodes of epistaxis. Cervical Magnetic Resonance Imaging (MRI) revealed a tumor mass involving 
right nasal cavity, right ethmoid, sphenoidal and maxillary sinuses.
For a differential diagnosis between metastatic gestational choriocarcinoma and primary choriocarcinoma in January 2019 
she underwent 18Fluorine-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG-PET/CT) 
scan that demonstrated intense uptake only in the nasal-ethmoid tumor mass showed by MRI. This was suggestive of primary 
nasal-ethmoid choriocarcinoma she received 3 courses of BEP – regimen and after β-HCG was reduced to 500 mIU/mL and 
18F-FDG-PET/CT scan showed a decreased uptake in tumor mass but the appearance of a new uptake in cervical lymph node 
which was analysed and reported as metastatic localization of choriocarcinoma. Therefore she was treated with 2 cycles of 
TIP-regimen. Subsequents 18F-FDG-PET/CT and MRI showed a complete tumor remission.
This case proved the fundamental role of PET/CT to make diagnosis of primitive choriocarcinoma and to exclude the hypothesis 
of distant metastasis.
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Choriocarcinoma is a highly malignant and rare tumor character-
ized by secretion of the beta-subunit-of-human-choriogonadotropin 
(β-HCG). In women, can distinguish two types of choriocarcinoma: 
gestational and non-gestational primary choriocarcinoma, which 
is extremely rare, arising from germ cells. We report a case of primary 
nasal choriocarcinoma with good response to chemotherapy [1, 2].
A 36-year-old woman gravida 0 and with history of 4 spontane-
ous abortion, in December 2018 referred to Otorhinolaryngology 
Department for repeated episodes of epistaxis. Cervical Magnetic 
Resonance Imaging (MRI) revealed a tumor mass involving right 
nasal cavity, right ethmoid, sphenoidal and maxillary sinuses. 
At histological examination, the tumor was composed of cohesive 
sheets of highly atypical mononucleate epithelioid tumor cells, minor 
component of plurinucleate cells referable to syncytiotrophoblast 
cells and areas of hemorrhage and necrosis. At immunohistochemi-
cal analysis tumor cells were positive for SALL4, GATA3, cytokeratin 
AE1/AE3, CK7, Glypican3 and β-HCG and negative for CD30, 
CD117, CX20 and S100. Ki67 proliferation index was > 90%. The 
final diagnosis was choriocarcinoma. 
For a differential diagnosis between metastatic gestational 
choriocarcinoma and primary choriocarcinoma in January 2019 she 
underwent 18Fluorine-Fluorodeoxyglucose Positron Emission 
Tomography/Computed Tomography (18F-FDG-PET/CT) scan 
that demonstrated intense uptake only in the nasal-ethmoid 
tumor mass showed by MRI. This was suggestive of primary 
nasal-ethmoid choriocarcinoma [3, 4]. The serum levels of β-HCG 
were 3839 mIU/mL while serum α-fetoprotein levels were normal. 
Treatment of choriocarcinoma includes tumor resection and 
chemotherapy with EMA/CO (etoposide, methotrexate, actin-
omicin D, cisplatin), DCF (docetaxel, cisplatin, 5-FU) and BEP 
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(bleomycin, etoposide and cisplatin), but patients who relapse 
after initial treatment or patients who didn’t respond completely 
to chemotherapy have a poor prognosis [5, 6]. Motzer et al. [7, 8] 
showed in a study that it is possible to obtain promising results with 
a combination of paclitaxel, ifosfamide and cisplatin (TIP) as a sal-
vage therapy.
According to literature, she received 3courses of BEP 
regimen and after that β-HCG was reduced to 500 mIU/mL and 
Figure 2. End-of-treatment images: A. PET/CT; B. Cervical MRI; both 
showed complete remission of nasal-ethmoidal mass
Figure 3. A. Hematoxylin and eosin stain showing mononucleated and plurinucleate tumor cells with striking cytologic atypia and central 
hemorrhage (200× magnification); B. Tumor cells positive for cytokeratin AE1/AE3 (200× magnification)
Figure 1. A. Staging PET/CT showed intense uptake in nasal-
ethmoidal mass; a. Fused image; b. MIP image; B. Staging Cervical 
MRI showed large tumor mass involving right nasal cavity, right 
ethmoid, sphenoidal and maxillary sinuses
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18F-FDG-PET/CT scan showed a decreased uptake in tumor 
mass, but the appearance of a new uptake in cervical lymph node 
which was analyzed and reported as metastatic localization of 
choriocarcinoma. Therefore she was treated with 2 cycles of TIP 
regimen. Subsequent 18F-FDG-PET/CT and MRI showed a com-
plete tumor remission. 
Due to aggressive and malignant biology of the disease, 
a correct identification of this tumor is important to start an effec-
tive therapy to improve the poor prognosis of choriocarcinoma. 
This case proved the fundamental role of PET/CT in establishing 
diagnosis of primitive choriocarcinoma and excluding the hypoth-
esis of distant metastasis.
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